Sign In
Buy AMGN
$347.01
+2.29 (+0.664%)
At Close: Jun 23, 2026
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:33pm, Tuesday, 23'rd Jun 2026
Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for ad
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
10:51am, Tuesday, 23'rd Jun 2026
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
2 Underrated Weight Loss Stocks to Buy and Hold
02:45am, Tuesday, 23'rd Jun 2026
They look well-positioned to grab a slice of the fast-growing anti-obesity market.
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
12:50pm, Friday, 19'th Jun 2026
Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 19'th Jun 2026
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
06:50pm, Wednesday, 17'th Jun 2026
The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Why Amgen (AMGN) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 17'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AMGN DCF Analysis: Intrinsic Value $292 vs Price $355
07:34am, Monday, 15'th Jun 2026
On June 15, 2026, we delve into the DCF analysis for Amgen Inc (AMGN), a company that has shown strong price performance over the past year, with a 23.1% increa
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaw
Drugmakers race to find a place in the next wave of obesity drugs
08:00am, Saturday, 13'th Jun 2026
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am
Amgen taps research firm to reassess Tavneos data
07:28pm, Thursday, 11'th Jun 2026
Amgen said it has signed up a research firm to independently review data for its drug, Tavneos, as it seeks to prove its benefits following the U.S. health regulator's proposal to withdraw it fr
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
07:14am, Thursday, 11'th Jun 2026
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sect
Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note
06:50pm, Wednesday, 10'th Jun 2026
In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
01:01pm, Wednesday, 10'th Jun 2026
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
